Active Biotech to Present at the JP Morgan 30th Annual Healthcare Conference

Lund, Sweden, January 4, 2012 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at the JP Morgan 30(th) Annual Healthcare Conference held
January 8-12, 2012 in San Francisco, US. During the presentation, an update
regarding Active Biotech's development programs will be provided.

The presentation will include the laquinimod MS project, a novel oral
immunomodulatory drug for the treatment of multiple sclerosis, licensed to Teva
Pharmaceutical Industries Ltd, the Phase III prostate cancer project TASQ in co-
development with Ipsen, as well as ANYARA, Active Biotech's novel concept for
tumor therapy in a Phase III study for renal cell cancer. Also, the project
57-57 and the pre-clinical ISI project will be presented.

The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to - www.activebiotech.com

The presentation will take place on January 12, at 8:00 am PST (Pacific Standard
Time) / 17.00 Central European Time.



About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer and ANYARA for use in cancer targeted therapy, primarily of
renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57- 57 for Systemic Sclerosis as well as
RhuDex(TM) for RA. Please visit www.activebiotech.com  for more information.


Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 08:30 am CET on January 4, 2012.



Contacts:
Active Biotech AB
Hans Kolam, CFO
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00




Active Biotech to Present at JP Morgan:
http://hugin.info/1002/R/1574671/490249pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
    other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
     originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1574671]